ACRIN-NSCLC-FDG-PET

Positron Emission Tomography Pre- and Post-treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma

This was a multicenter clinical trial by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group (now part of NRG) using FDG-PET imaging both pre- and post-chemoradiotherapy.

The objective of the ACRIN 6668 multi-center clinical trial was to determine if the PET standardized uptake value (SUV) measurement from FDG-PET imaging shortly after treatment is a useful predictor of long-term clinical outcome (survival) after definitive chemoradiotherapy. Eligible patients were those older than 18 years with AJCC-criteria clinical stage IIB/III non-small cell lung carcinoma who were being planned for definitive concurrent chemoradiotherapy (inoperable disease).

Primary Aim Findings: Higher post-treatment tumor SUV (SUVpeak, SUVmax) is associated with worse survival in stage III NSCLC, although a clear SUV cutoff value for routine clinical use as a prognostic factor was uncertain [1]. Later analyses found that larger pre-treatment metabolic tumor volumes (MTVs) were associated with significantly worse overall survival [2]. Other secondary analyses found potentially predictive image texture biomarkers.

Study Design Summary: Patients received conventional concurrent platinum-based chemoradiotherapy without surgery; post-radiotherapy consolidation chemotherapy was allowed. A baseline whole-body FDG-PET scan was performed prior to therapy. A second post-treatment whole-body FDG-PET scan occurred approximately 14 weeks after radiotherapy (at least 4 weeks after adjuvant chemotherapy).

Pre-treatment FDG-PET scans were performed on ACRIN-qualified scanners. Post-treatment FDG-PET scans were required to be performed within 12–16 weeks after completion of therapy, using the same scanner as that used for the pre-treatment scans.

Acknowledgements

This shared data set was provided in collaboration with the American College of Radiology Core Lab. Many thanks are due to the ACRIN 6668 trial team, and all the patients participating in the study.

This study was supported by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group (now part of NRG) which received funding from the National Cancer Institute through UO1 CA080098 and UO1 CA079778.

資料與資源

此資料集沒有資料

額外的資訊

欄位
最後更新 十二月 3, 2019, 14:28 (CST)
建立 二月 14, 2019, 10:19 (CST)

推薦資料集:


  • 受(處)理刑事案件嫌疑犯人數─按機關別分

    付費方式 免費
    更新頻率 不定期
    受(處)理刑事案件嫌疑犯人數─按機關別分 (資料起始時間:89年01月;刑事案件別)
  • 18歲以上國人自覺健康良好的百分比

    付費方式 免費
    更新頻率 不定期
    調查受訪者回答自覺健康狀況「好」或「很好」的百分比。 資料來源:本署健康危害行為監測調查。
  • 國家教育研究院-科學教育學術名詞

    付費方式 免費
    更新頻率 不定期
    科學教育英中對照名詞等資訊。
  • 106年度臺中市地方總預算(案)附屬單位預算及綜計表-營業基金-損益綜計表(依基金別分列)

    付費方式 免費
    更新頻率 不定期
    106年度臺中市地方總預算(案)附屬單位預算及綜計表-營業基金-損益綜計表(依基金別分列)
  • 社區照顧關懷據點

    付費方式 免費
    更新頻率 不定期
    社區照顧關懷據點